Limula has announced a new partnership with Institut Paoli-Calmettes (IPC) to characterise the cell processing capabilities of LimONE for haematopoietic stem cell (HSC) transplantation applications.
Based in Marseille, France, IPC is internationally recognised as a leading treatment centre for cell therapies in haematological cancers and runs one of the most established autologous and allogeneic stem cell transplantation programmes in Europe.
The centre will adopt LimONE to automate critical steps, including cryoprotectant removal before infusion, enhancing treatment quality and consistency.
LimONE is Limula’s automated and closed platform for autologous HSC transplantation, a procedure impacting nearly 50,000 patients annually in Europe.
This collaboration highlights LimONE’s versatility and the potential to significantly improve cancer patient care.
After promising preliminary results using an early prototype of Limula’s technology in 2022 and with strong confirmatory results earlier in 2025, IPC will further document the performance of LimONE.
The goal of the collaboration is to advance automated cell product processing, with a focus on the removal of cryoprotectants and cell debris from thawed apheresis products.
A fast and efficient wash is critical for maintaining the quality and consistency of the cell product and also significantly improves the patient experience.
“We are impressed with the improvements we saw during the development of LimONE and are eager to adopt the platform into our facility,” said Boris Calmels, Head of the Cellular Manufacturing Unit at IPC.
“I see strong potential for Limula’s technology to play a key role in improving both our cell processes and the patient’s experience during stem cell transplantation.”
Luc Henry, CEO of Limula, added: “This collaboration is a powerful demonstration of the versatility of our platform."
"We are proud to support IPC in their mission to deliver high-quality transplantation products to their patients.”